Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

13.90
-0.3000-2.11%
Volume:507.89K
Turnover:7.01M
Market Cap:1.44B
PE:-10.29
High:14.52
Open:14.16
Low:13.56
Close:14.20
52wk High:14.93
52wk Low:7.23
Shares:103.52M
Float Shares:88.69M
Volume Ratio:0.73
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3513
EPS(LYR):-1.4747
ROE:-39.80%
ROA:-25.97%
PB:3.77
PE(LYR):-9.43

Loading ...

ORIC Pharmaceuticals Q1 EPS $(0.34) Misses $(0.32) Estimate

Benzinga Earnings
·
May 05

Oric initiates Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in mCRPC

Reuters
·
May 05

Oric Q1 FY26 net loss widens to $35.77 million; R&D expenses rise to $31.44 million

Reuters
·
May 05

BRIEF-ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million

Reuters
·
May 05

Oric Pharmaceuticals Q1 Operating Expenses USD 39.619 Million

THOMSON REUTERS
·
May 05

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

GlobeNewswire
·
May 05

ORIC Pharma grants 216,000 stock options, 35,000 RSUs to new employees

Reuters
·
May 02

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 02

U.S. Earnings Preview: After Market Close May 1

Dow Jones
·
May 02

Oric Pharmaceuticals announces annual shareholder meeting notice

Reuters
·
Apr 29

A Look At ORIC Pharmaceuticals (ORIC) Valuation After New Rinzimetostat AACR Prostate Cancer Data

Simply Wall St.
·
Apr 22

Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR

TIPRANKS
·
Apr 18

Oric presents preclinical AACR data backing rinzimetostat in prostate cancer models

Reuters
·
Apr 18

Why ORIC Pharmaceuticals (ORIC) Is Up 14.2% After Advancing Rinzimetostat Combo Into Phase 3 Trial

Simply Wall St.
·
Apr 11

JonesTrading Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Apr 07

Oric Pharma grants 80,000 stock options in Nasdaq Rule 5635(c)(4) inducement award

Reuters
·
Apr 04

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 04

Analysts Offer Insights on Healthcare Companies: Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Apr 02

Oric selloff brings attractive entry point, says H.C. Wainwright

TIPRANKS
·
Apr 02

Oric Pharmaceuticals Down Nearly 39%, on Track for Record Percent Decrease -- Data Talk

Dow Jones
·
Apr 02